Insulet Co. (NASDAQ:PODD) Shares Sold by Bank of Nova Scotia

Bank of Nova Scotia trimmed its holdings in shares of Insulet Co. (NASDAQ:PODDGet Rating) by 19.5% during the second quarter, HoldingsChannel reports. The institutional investor owned 1,195 shares of the medical instruments supplier’s stock after selling 290 shares during the quarter. Bank of Nova Scotia’s holdings in Insulet were worth $260,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Reynders McVeigh Capital Management LLC lifted its position in Insulet by 1.8% during the second quarter. Reynders McVeigh Capital Management LLC now owns 2,213 shares of the medical instruments supplier’s stock valued at $482,000 after buying an additional 40 shares in the last quarter. Washington Trust Advisors Inc. raised its stake in shares of Insulet by 25.0% during the second quarter. Washington Trust Advisors Inc. now owns 260 shares of the medical instruments supplier’s stock valued at $57,000 after purchasing an additional 52 shares during the period. Quadrant Capital Group LLC raised its stake in shares of Insulet by 19.0% during the first quarter. Quadrant Capital Group LLC now owns 420 shares of the medical instruments supplier’s stock valued at $112,000 after purchasing an additional 67 shares during the period. Cresset Asset Management LLC raised its stake in shares of Insulet by 6.6% during the first quarter. Cresset Asset Management LLC now owns 1,102 shares of the medical instruments supplier’s stock valued at $293,000 after purchasing an additional 68 shares during the period. Finally, Private Advisor Group LLC raised its stake in shares of Insulet by 4.1% during the second quarter. Private Advisor Group LLC now owns 1,817 shares of the medical instruments supplier’s stock valued at $396,000 after purchasing an additional 71 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PODD. Jefferies Financial Group began coverage on shares of Insulet in a research note on Wednesday, October 12th. They set a “hold” rating and a $260.00 price objective on the stock. Robert W. Baird lifted their price objective on shares of Insulet from $300.00 to $315.00 and gave the company an “outperform” rating in a research note on Friday, November 4th. Raymond James lifted their price objective on shares of Insulet from $280.00 to $320.00 and gave the company an “outperform” rating in a research note on Friday, November 4th. Barclays began coverage on shares of Insulet in a research note on Monday, October 17th. They set an “equal weight” rating and a $238.00 price objective on the stock. Finally, BTIG Research lifted their price target on shares of Insulet from $285.00 to $320.00 in a research note on Friday, November 4th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $300.62.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Michael P. Spears sold 13,658 shares of the business’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $308.99, for a total transaction of $4,220,185.42. Following the completion of the sale, the senior vice president now owns 8,792 shares in the company, valued at $2,716,640.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Shacey Petrovic sold 15,000 shares of the company’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $231.80, for a total value of $3,477,000.00. Following the completion of the sale, the director now owns 13,695 shares of the company’s stock, valued at $3,174,501. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael P. Spears sold 13,658 shares of the company’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $308.99, for a total transaction of $4,220,185.42. Following the completion of the sale, the senior vice president now directly owns 8,792 shares of the company’s stock, valued at approximately $2,716,640.08. The disclosure for this sale can be found here. Insiders sold a total of 31,558 shares of company stock worth $8,463,481 over the last 90 days. Insiders own 0.90% of the company’s stock.

Insulet Stock Down 0.6 %

PODD stock opened at $295.53 on Monday. The company has a debt-to-equity ratio of 3.22, a current ratio of 3.98 and a quick ratio of 3.00. Insulet Co. has a 1-year low of $181.00 and a 1-year high of $320.00. The firm has a fifty day moving average price of $254.25 and a two-hundred day moving average price of $240.47. The firm has a market cap of $20.52 billion, a price-to-earnings ratio of 1,231.38 and a beta of 0.79.

Insulet Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Featured Articles

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDGet Rating).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.